Rallybio Co. (NASDAQ:RLYB) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Rallybio Co. (NASDAQ:RLYB) have earned an average rating of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $9.75.

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Rallybio in a research note on Monday, January 13th.

Institutional Investors Weigh In On Rallybio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hsbc Holdings PLC bought a new position in Rallybio in the second quarter valued at about $25,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Rallybio in the second quarter valued at approximately $61,000. Almitas Capital LLC bought a new position in Rallybio in the 2nd quarter valued at approximately $135,000. FMR LLC boosted its position in Rallybio by 1.1% during the 3rd quarter. FMR LLC now owns 2,315,480 shares of the company’s stock worth $2,709,000 after buying an additional 25,422 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Rallybio by 11.4% during the 3rd quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock worth $287,000 after acquiring an additional 24,980 shares during the last quarter. 90.34% of the stock is currently owned by institutional investors.

Rallybio Trading Up 2.1 %

RLYB opened at $0.89 on Wednesday. Rallybio has a 1 year low of $0.84 and a 1 year high of $3.46. The stock has a fifty day moving average price of $1.00 and a 200 day moving average price of $1.10. The stock has a market cap of $37.09 million, a price-to-earnings ratio of -0.56 and a beta of -1.48.

Rallybio (NASDAQ:RLYB) last posted its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.10. The company had revenue of $0.30 million during the quarter. As a group, sell-side analysts forecast that Rallybio will post -1.34 earnings per share for the current fiscal year.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.